USA: Perioperative Chemo Improves Progression-Free Survival in Pancreatic Cancer

For patients with resectable pancreatic ductal adenocarcinoma (PDAC), the 12-month progression-free survival (PFS) may be increased with neoadjuvant modified 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (mFOLFIRINOX), according to a study published online June 20 in JAMA Oncology.

Michael Cecchini, M.D., from the Yale University School of Medicine in New Haven, Connecticut, and colleagues examined whether neoadjuvant mFOLFIRINOX leads to early control of micrometastasis and improves survival among patients with resectable PDAC in an open-label phase 2 trial. Forty-six patients received six cycles of neoadjuvant mFOLFIRINOX before surgery and six cycles of adjuvant mFOLFIRINOX.

Source: Advances and More licensed by HealthDay

https://advancesandmore.com/advances_article.htm?id=MDcwMDQ0MmQtYjRiNS00NzM4LTk3MDMtM2RjMzJkNjhjMzBh&client=Nw%3D%3D&section=undefined